

# Cathy Eng

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8298880/cathy-eng-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244 papers	13,140 citations	54 h-index	112 g-index
266 ext. papers	15,491 ext. citations	6.2 avg, IF	6.03 L-index

#	Paper	IF	Citations
244	Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report.. <i>Clinical Colorectal Cancer</i> , <b>2022</b> ,	3.8	0
243	A comprehensive framework for early-onset colorectal cancer research.. <i>Lancet Oncology</i> , <b>2022</b> , ,	21.7	7
242	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.. <i>Oncologist</i> , <b>2022</b> , 27, 40-47	5.7	0
241	Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis.. <i>BMJ Open</i> , <b>2022</b> , 12, e052376	3	0
240	Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	2
239	Clinical and pathologic features correlated with rare favorable survival in patients with mutated colorectal cancer.. <i>Journal of Gastrointestinal Oncology</i> , <b>2022</b> , 13, 647-656	2.8	
238	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2213588	10.4	2
237	Safety considerations with new treatment regimens for anal cancer. <i>Expert Opinion on Drug Safety</i> , <b>2021</b> , 20, 889-902	4.1	0
236	First-in-human PET imaging and estimated radiation dosimetry of L-[5-C]-glutamine in patients with metastatic colorectal cancer. <i>Journal of Nuclear Medicine</i> , <b>2021</b> ,	8.9	4
235	Immunotherapy for GI Cancers: Who Benefits, Who Does Not, and Promising Strategies to Expand Use. <i>Advances in Oncology</i> , <b>2021</b> , 1, 283-295		
234	CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , <b>2021</b> , 12, 1037-1045	3.3	0
233	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. <i>Cancer Medicine</i> , <b>2021</b> , 10, 4269-4281	4.8	2
232	Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. <i>BMJ Supportive and Palliative Care</i> , <b>2021</b> , 11, 170-179	2.2	6
231	Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2021</b> , 26, e261-e269	5.7	3
230	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 797-804	8.7	4
229	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, 607-614	2.3	4
228	Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration. <i>Cancer Reports</i> , <b>2021</b> , e1508	1.5	

227	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 3151-3162	3.6	1
226	Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, e210-e213	3.8	
225	Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2021</b> ,	3.8	0
224	In Reply. <i>Oncologist</i> , <b>2020</b> , 25, e1252-e1253	5.7	
223	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2510-2518	2.2	37
222	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , <b>2020</b> , 25, e1426-e1427	5.7	5
221	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, e189-e199	3.8	
220	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 248-255.e6	3.8	2
219	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1924-1931	12.9	26
218	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , <b>2020</b> , 25, e936-e945	5.7	356
217	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , <b>2020</b> , 17, 757-770	19.4	82
216	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1763-1773	4.3	1
215	Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. <i>Gastroenterology</i> , <b>2020</b> , 159, 1605-1608	13.3	4
214	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 955-966	3.6	7
213	TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?. <i>Lancet Oncology</i> , <b>2020</b> , 21, 326-327	21.7	1
212	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , <b>2020</b> , 11, 1334-1343	3.3	6
211	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2782-2797	2.2	63
210	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. <i>Journal of Experimental Pharmacology</i> , <b>2020</b> , 12, 475-485	3	3

209	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1262-1270	8.7	2
208	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 525	2.3	1
207	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 901-908	3.5	3
206	Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
205	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 151, 56-57	5.3	1
204	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2028644	10.4	4
203	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 2139-2160	4	1
202	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 216-225	7.1	11
201	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 849-861	21.7	201
200	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 505-510	8.7	14
199	More questions regarding HIPEC in colorectal carcinomatosis. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 744-745	18.8	2
198	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 301-306	3.8	1
197	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5852-5858	12.9	58
196	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , <b>2019</b> , 58, 662-674	11.8	12
195	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1247-1263	5.4	19
194	Managing Non-Hepatic Metastatic Sites: Lung and CNS <b>2019</b> , 495-508		
193	Squamous Cell Carcinoma of the Anal Canal <b>2019</b> , 175-184		
192	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	3

191	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	5
190	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 523-534	4	2
189	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , <b>2019</b> , 269, 917-923	7.8	78
188	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3263-3272	12.9	41
187	Anal Cancer <b>2018</b> , 149-162		
186	The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , <b>2018</b> , 55, 1276-1285	4.8	21
185	Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. <i>Current Oncology Reports</i> , <b>2018</b> , 20, 3	6.3	9
184	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 632-637	2.7	9
183	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 181-188	12.9	89
182	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , <b>2018</b> , 67, 1095-1102	19.2	16
181	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 903-908	7.3	9
180	Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. <i>Hpb</i> , <b>2018</b> , 20, 1150-1156	3.8	6
179	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , <b>2018</b> , 3, 595-600	3.3	3
178	Physician interpretation of genomic test results and treatment selection. <i>Cancer</i> , <b>2018</b> , 124, 966-972	6.4	8
177	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1062-1072	12.9	143
176	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 959-967	2.2	13
175	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 941-950	5.9	2
174	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196245	3.7	2

173	Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 102, 102-108	4	11
172	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 35-45	7.5	20
171	Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2017</b> , 40, 163-166	2.7	14
170	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2017</b> , 40, 277-282	2.7	12
169	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , <b>2017</b> , 122, 146-151	5.3	32
168	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 446-453	21.7	223
167	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4146-4154	12.9	29
166	Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. <i>Cancer</i> , <b>2017</b> , 123, 1989-1997	6.4	35
165	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , <b>2017</b> , 2, 455-464	3.3	13
164	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , <b>2017</b> , 123, 3367-3376	6.4	12
163	Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2595	3.1	1
162	Measurement of DNA damage in peripheral blood by the $\gamma$ H2AX assay as predictor of colorectal cancer risk. <i>DNA Repair</i> , <b>2017</b> , 53, 24-30	4.3	14
161	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183949	3.7	21
160	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3240-3261	2.2	351
159	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2631-2638	2.2	39
158	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	19
157	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, 990-997	2.8	16
156	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 3667-3672	3.1	7

155	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 4051-4058	3.1	19
154	Pharmacotherapy of Anal Cancer. <i>Drugs</i> , <b>2017</b> , 77, 1519-1530	12.1	4
153	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 1542-1550	6.6	36
152	Neoadjuvant Strategies: Locally Advanced Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , <b>2017</b> , 30, 383-386	2.3	8
151	Global and targeted serum metabolic profiling of colorectal cancer progression. <i>Cancer</i> , <b>2017</b> , 123, 4066-4074	4.7	38
150	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 2646-2654	3.1	19
149	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , <b>2017</b> , 17, 331	4.8	7
148	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 187-193	3.1	41
147	Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 1376-1377	3.1	9
146	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , <b>2017</b> , 26, 133-142	2.7	6
145	Metastasis regulation by PPARD expression in cancer cells. <i>JCI Insight</i> , <b>2017</b> , 2, e91419	9.9	38
144	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173345	3.7	49
143	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 39268-39279	3.3	39
142	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. <i>Clinical Advances in Hematology and Oncology</i> , <b>2017</b> , 15, 968-961	0.6	2
141	POLE mutations in colorectal cancer: a new biomarker?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 176-177	18.8	7
140	Multidisciplinary management of stage IV colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , <b>2016</b> , 27, 213-218	0.3	1
139	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 177-86	7.5	40
138	Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 76250-76260	3.3	66



137	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , <b>2016</b> , 7, 67495-67506	3.3	32
136	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. <i>Oncotarget</i> , <b>2016</b> , 7, 54627-54631	3.3	39
135	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 721-726	2.8	6
134	Epidermal growth factor receptor inhibition in metastatic anal cancer. <i>Anti-Cancer Drugs</i> , <b>2016</b> , 27, 804-814	2.4	16
133	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , <b>2016</b> , 21, 563-70	5.7	26
132	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. <i>Oncology</i> , <b>2016</b> , 90, 127-35	3.6	20
131	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1803-12	2.2	65
130	Challenges of efficacy assessments in pseudomyxoma peritonea. <i>Oncologist</i> , <b>2015</b> , 20, e3-4	5.7	2
129	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. <i>Lancet Oncology</i> , <b>2015</b> , 16, 878-9	21.7	3
128	Colorectal Cancer Survivorship Management <b>2015</b> , 71-93		
127	Quality of life after intensity-modulated radiation therapy for anal cancer. <i>Journal of Radiation Oncology</i> , <b>2015</b> , 4, 291-298	0.7	4
126	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , <b>2015</b> , 20, 1247-52	5.7	26
125	Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. <i>JAMA Surgery</i> , <b>2015</b> , 150, 402-9	5.4	107
124	Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. <i>Indian Journal of Surgical Oncology</i> , <b>2015</b> , 6, 198-206	0.7	6
123	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 271-81	7.5	80
122	Perspectives on clinical trials for gastrointestinal malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2015</b> , 40-3	7.1	1
121	Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 6, E82-5	2.8	4
120	Atypical metastatic presentations in colorectal cancer: a case series. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, e1-4	3.8	9



119	Optimal management of squamous cell carcinoma of the anal canal: where are we now?. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 877-86	3.5	6
118	Optimal treatment strategies for anal cancer. <i>Current Treatment Options in Oncology</i> , <b>2014</b> , 15, 443-55	5.4	5
117	Cetuximab in refractory squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Cancer</i> , <b>2014</b> , 45 Suppl 1, 198-200	1.6	5
116	Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 164-71	3.8	77
115	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. <i>Cancer</i> , <b>2014</b> , 120, 1162-70	6.4	33
114	Long- Versus Short-Course Radiotherapy for Rectal Cancer <b>2014</b> , 200-217		
113	Controversies in Advanced Disease [Surgical Approaches for Metastatic Resection <b>2014</b> , 227-242		
112	What is the Role of Surveillance for Colorectal Cancer? <b>2014</b> , 261-271		
111	Surgery for Anal Cancer <b>2014</b> , 163-176		
110	Controversies in Adjuvant Chemotherapy <b>2014</b> , 177-199		1
109	How Histopathology Affects the Management of the Multidisciplinary Team <b>2014</b> , 67-83		
108	Neoadjuvant Therapy Without Surgery for Early Stage Rectal Cancer? <b>2014</b> , 126-149		
107	Minimally Invasive Surgery for Rectal Cancer and Robotics <b>2014</b> , 150-162		
106	The Young Patient with Colorectal Cancer [Genetic Counseling Discussion <b>2014</b> , 273-285		
105	Palliative Care Vignettes <b>2014</b> , 292-297		
104	More Treatment is not Necessarily Better [Limited Options for Chemotherapeutic Radiosensitization <b>2014</b> , 218-226		
103	Best Practices of Supportive Care While Receiving Chemotherapy <b>2014</b> , 286-291		
102	Controversies in Chemotherapy in Advanced Colorectal Cancer <b>2014</b> , 243-260		

101	Management of Adenomas <b>2014</b> , 51-65		1
100	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 109, 740-5	2.8	45
99	A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. <i>Cancer Research</i> , <b>2014</b> , 74, 5955-62	10.1	47
98	Radical Colonic Resection <b>2014</b> , 85-103		
97	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2975-84	2.2	77
96	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4240-50	12.9	83
95	Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2014</b> , 37, 461-6	2.7	49
94	Extralevator AbdominoPerineal Excision (ELAPE) for Advanced Low Rectal Cancer <b>2014</b> , 104-125		
93	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 301-5	4	17
92	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 1223-31	3.9	71
91	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , <b>2014</b> , 5, 6584-93	3.3	12
90	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. <i>Oncotarget</i> , <b>2014</b> , 5, 11133-42	3.3	69
89	Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2014</b> , 7, 65-8		4
88	Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. <i>Cancer</i> , <b>2013</b> , 119, 3769-75	6.4	22
87	Will PICCOLO affect metastatic colorectal cancer therapy?. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 679-80	21.7	
86	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. <i>Cancer</i> , <b>2013</b> , 119, 4231-41	6.4	39
85	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1044-6	3.2	2
84	Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. <i>Oncologist</i> , <b>2013</b> , 18, 1270-7	5.7	30

83	Metformin use and improved response to therapy in rectal cancer. <i>Cancer Medicine</i> , <b>2013</b> , 2, 99-107	4.8	70
82	Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. <i>Annals of Surgery</i> , <b>2013</b> , 257, 1072-8	7.8	61
81	The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e77117	3.7	84
80	The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 199-199	2.2	1
79	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. <i>Carcinogenesis</i> , <b>2012</b> , 33, 1327-31	4.6	39
78	Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 623-33	5.5	66
77	Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 191-4	3.8	15
76	Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1770-6	2.2	327
75	The promise of mTOR inhibitors in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 1775-88	5.9	23
74	Role of the MET/IGF axis in colorectal cancer: precepts and prospects. <i>Colorectal Cancer</i> , <b>2012</b> , 1, 329-340.	0.8	6
73	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , <b>2012</b> , 8, 233-242	1	
72	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. <i>Cancer</i> , <b>2012</b> , 118, 6188-98	6.4	10
71	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1646-51	4.3	120
70	Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3982-91	12.9	63
69	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , <b>2012</b> , 9, 065004	3	7
68	Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3180-7	12.9	41
67	The current state of targeted agents in rectal cancer. <i>International Journal of Surgical Oncology</i> , <b>2012</b> , 2012, 406830	0.9	5
66	Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. <i>Carcinogenesis</i> , <b>2012</b> , 33, 841-7	4.6	4

65	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , <b>2012</b> , 1, 15-16	0.8	
64	Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 661-661	2.2	2
63	Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , <b>2012</b> , 3, 161-9	0.7	2
62	The current landscape of locally advanced rectal cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 649-59	9.4	61
61	Fatal diffuse alveolar damage associated with oxaliplatin administration. <i>Clinical Colorectal Cancer</i> , <b>2011</b> , 10, 198-202	3.8	13
60	Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 411-6	2.7	9
59	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. <i>Cancer</i> , <b>2011</b> , 117, 3713-22	6.4	46
58	Cetuximab in the treatment of patients with colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , <b>2011</b> , 11, 937-49	5.4	38
57	A novel platform for detection of CK+ and CK- CTCs. <i>Cancer Discovery</i> , <b>2011</b> , 1, 580-6	24.4	162
56	High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1083-90	2.2	293
55	Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4531-40	12.9	31
54	Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 573-80	2.7	125
53	Carcinoma of the anal canal: small steps in treatment advances. <i>Clinical Advances in Hematology and Oncology</i> , <b>2011</b> , 9, 662-9	0.6	
52	American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 493-508	2.2	340
51	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 453-9	2.2	383
50	The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. <i>Oncologist</i> , <b>2010</b> , 15, 73-84	5.7	38
49	Are herbal medicines ripe for the cancer clinic?. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 45ps41	17.5	11
48	Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2549-55	2.2	151

47	Long-term survival and recurrence outcomes following surgery for distal rectal cancer. <i>Annals of Surgical Oncology</i> , <b>2010</b> , 17, 2863-9	3.1	87
46	Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 76, 824-30	4	155
45	Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1098-105	4	48
44	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. <i>Cancer</i> , <b>2010</b> , 116, 316-22	6.4	82
43	Long-term quality of life after radiotherapy for the treatment of anal cancer. <i>Cancer</i> , <b>2010</b> , 116, 822-9	6.4	93
42	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). <i>Cancer</i> , <b>2010</b> , 116, 2053-63	6.4	47
41	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , <b>2010</b> , 116, 4086-94	6.4	22
40	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. <i>Cancer</i> , <b>2010</b> , 116, 5325-35	6.4	67
39	Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. <i>Molecular Carcinogenesis</i> , <b>2010</b> , 49, 974-80	5	11
38	Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 77, 60-5	4	88
37	Commentary: practice patterns and potential impact on quality measures for a practicing physician. <i>Journal of Oncology Practice</i> , <b>2009</b> , 5, 233-5	3.1	2
36	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3677-83	2.2	955
35	Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2009</b> , 6, 207-18	19.4	49
34	Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 6, 16-7		1
33	Practical application of a calculator for conditional survival in colon cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5938-43	2.2	80
32	Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2598-603	2.2	167
31	Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. <i>Cancer</i> , <b>2009</b> , 115, 5432-40	6.4	59
30	Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 818-23	4	46

29	Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 75, 791-4	4	23
28	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. <i>Annals of Surgical Oncology</i> , <b>2009</b> , 16, 2181-7	3.1	50
27	A twenty-year experience with adenocarcinoma of the anal canal. <i>Diseases of the Colon and Rectum</i> , <b>2009</b> , 52, 1375-80	3.1	40
26	Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 55-9	3.8	6
25	Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 65-8	3.8	23
24	Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. <i>Clinical Colorectal Cancer</i> , <b>2008</b> , 7, 338-42	3.8	
23	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2311-9	2.2	757
22	Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2000-5	2.2	15
21	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , <b>2008</b> , 13, 629-42	3.7	9
20	Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5344-51	2.2	458
19	Treatment options in metastatic squamous cell carcinoma of the anal canal. <i>Current Treatment Options in Oncology</i> , <b>2008</b> , 9, 400-7	5.4	17
18	Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 71, 1175-80	4	48
17	Prognostic factors for squamous cell cancer of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2008</b> , 2, 10-4		15
16	K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2008</b> , 6, 174-5	0.6	5
15	Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6 Suppl 2, S53-9	3.8	1
14	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. <i>Cancer</i> , <b>2007</b> , 109, 1750-5	6.4	247
13	Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. <i>Cancer</i> , <b>2007</b> , 110, 2761-7	6.4	294
12	Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 68, 794-800	4	147



11	Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. <i>Journal of Gastrointestinal Surgery</i> , <b>2007</b> , 11, 1498-504; discussion 1504-5	3.3	135
10	Biological agents versus chemotherapy in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 1251-71	4	2
9	Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2065-72	2.2	1026
8	Anal cancer: current and future methodology. <i>Cancer Investigation</i> , <b>2006</b> , 24, 535-44	2.1	33
7	Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2006</b> , 29, 219-24	2.7	128
6	Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 762-71	4	102
5	Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. <i>Annals of Surgery</i> , <b>2005</b> , 241, 715-22, discussion 722-4	7.8	805
4	Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 1098-105	4	156
3	Chemotherapy and radiation of anal canal cancer: the first approach. <i>Surgical Oncology Clinics of North America</i> , <b>2004</b> , 13, 309-20, viii	2.7	16
2	The treatment of colorectal carcinoma: standard chemotherapy and beyond. <i>Clinical Advances in Hematology and Oncology</i> , <b>2004</b> , 2, 592-8	0.6	1
1	Colorectal cancer during pregnancy or postpartum: Case series and literature review. <i>Obstetric Medicine</i> , 1753495X2110412	1.5	0